Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARCH CAPITAL GROUP LTD.ACGL · Entity 3120 | Director | June 03, 2026 | June 04, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARCH CAPITAL GROUP LTD.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Depositary Shares, Series FSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Sale · Disposed 3,000 · Balance 0 F1: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share. F2: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.57 to $19.80. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share.
F2: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.57 to $19.80. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission.
Dyne Therapeutics, Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,000 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Purchase · Acquired 2,500 · Balance 27,000 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOGEN INC.
Report date December 31, 2022 · Filed January 27, 2023
Section 16 reporting ended · disclosed 2023-01-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,025 |
Reported balance
After 2022-06-07 transaction · row 1
1 source rowRow 1 · 2022-06-07 · Gift · Disposed 150 · Balance 8,025 |
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 6,693 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 6,364 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 2,980 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 26,818 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2018 Filed Mar 8, 2018 17:49 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerRestricted Stock Units · Derivative | 6,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010675 · form4.xml · derivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,364 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F3 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 17:49 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerCommon Stock | 6,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010675 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:15 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantRestricted Stock Units · Derivative | 6,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003811 · form4.xml · derivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,364 Underlying: Common Stock · 6,364 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 2, 2018 22:26 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | Disposition to issuerSeries C Non-Cumulative Preferred Shares (non-convertible) | 2,146 | $25.00 | $53,650.00 |
DisclosureSEC source: 0001179110-18-000134 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 25, 2017 Filed Sep 26, 2017 15:07 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | Disposition to issuerSeries C Non-Cumulative Preferred Shares (non-convertible) | 695 | $25.00 | $17,375.00 |
DisclosureSEC source: 0001179110-17-012698 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,146 Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 21:08 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | Disposition to issuerSeries C Non-Cumulative Preferred Shares (non-convertible) | 4,659 | $25.00 | $116,475.00 |
DisclosureSEC source: 0001179110-17-012435 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,841 Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 20:50 UTC | Bioverativ Inc. BIVV · Entity 168487 | PurchaseCommon Stock | 1,000 | $59.19 | $59,189.90 |
DisclosureSEC source: 0001127602-17-025422 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,693 Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:29 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 1,084 | $256.31 | $277,840.04 |
DisclosureSEC source: 0001127602-17-021193 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,330 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:48 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021096 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,414 F1 · balance_after: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| May 24, 2017 Filed May 24, 2017 21:03 UTC | Bioverativ Inc. BIVV · Entity 168487 | PurchaseCommon Stock | 700 | $53.79 | $37,656.01 |
DisclosureSEC source: 0001127602-17-019291 · form4.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,693 Read SEC document |
| May 24, 2017 Filed May 24, 2017 21:03 UTC | Bioverativ Inc. BIVV · Entity 168487 | PurchaseCommon Stock | 1,300 | $53.90 | $70,068.44 |
DisclosureSEC source: 0001127602-17-019291 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,993 Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:55 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-006696 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,439 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2018. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:55 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 1,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-006696 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,668 F1 · price: Represents shares granted as part of the director-elected annual retainer for serving as a director of the Issuer. Read SEC document |
| April 17, 2017 Filed Apr 17, 2017 20:06 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantCommon Stock | 1,056 | $56.83 | $60,012.48 |
DisclosureSEC source: 0001127602-17-014846 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 F1 · shares: The common stock was issued to the reporting person pursuant to the 2017 Non-Employee Directors Plan in lieu of an annual retainer fee of $60,000. F2 · balance_after: Includes 2,637 shares of common stock acquired in a pro rata distribution by Biogen in connection with the spin off of Bioverativ by Biogen on February 1, 2017. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 21:44 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 2,974 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-006628 · form4.xml · derivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974 Underlying: Common Stock · 2,974 shares Expires 2027-02-14 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 21:44 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 26,770 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-006628 · form4.xml · derivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,770 Underlying: Common Stock · 26,770 shares Expires 2027-02-14 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. Read SEC document |
| February 14, 2017 Filed Mar 27, 2017 20:12 UTC Amendment | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 2,980 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-012935 · form4a.xml · derivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,980 Underlying: Common Stock · 2,980 shares Expires 2027-02-14 F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. Read SEC document |
| February 14, 2017 Filed Mar 27, 2017 20:12 UTC Amendment | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 26,818 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-012935 · form4a.xml · derivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,818 Underlying: Common Stock · 26,818 shares Expires 2027-02-14 F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 21:05 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseDepositary Shares | 6,000 | $21.88 | $131,271.00 |
DisclosureSEC source: 0001179110-16-031892 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F2 · security: Each Depositary Shares represents 1/1,000th interest in a Series E Non-Cumulative Preferred Share (non-convertible). F1 · price: Represents a weighted average purchase price; the purchase prices range from $21.74 to $21.98. Upon request, the full purchase information regarding the number of shares purchased at each price increment will be provided to the Commission or to the security holder of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.